Skip to content

AACR Annual Meeting 2026

April 17–22, 2026 · San Diego · 2418 items

← Next-generation ADCs: payload innovation

HER2

Clinical trial

11 people · 11 posts · 8 abstracts

Heat trend for this story

Heat now 1·Peak in the comparable set 2 (Apr 22 11:00)·Change over 24h in the comparable set –·Participants now 3

Participants counted3
0123
Heat over time
00.511.52Apr22Apr22Apr22Apr23

Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.

Records
Drug / trialReadoutSetting
T-DXd + pertuzumabtrastuzumabHER2#BREASTCANCERPFS HR 0.56 (40.7 vs 26.9 mo)DESTINY-Breast09 · 1L HER2+ mBC · Phase 3
zanidatamab 新辅助zanidatamabHER2No-chemo pCR 30%, HER2 down 56%NeoZanHER · early HER2+++

T-DXd is already rewriting the first-line standard.

Other cases in this chapter

zanidatamab binds two HER2 domains at once (the trastuzumab and pertuzumab sites) and does not lean on chemo cytotoxicity. T-DXd is the other pole: an ADC payload pushing the first-line standard up, at the cost of interstitial lung disease.

Records
Drug / trialReadoutSetting
T-DXd + pertuzumabtrastuzumabHER2#BREASTCANCERPFS HR 0.56; ILD ~12%, including 2 grade 5DESTINY-Breast09 · 1L HER2+

First-line HER2 is being rewritten by an ADC.

Other cases in this chapter
Evidence
CT011
Genomic HER2 amplification predicts for complete clinical response in a phase II study of induction tucatinib and trastuzumab combined with chemotherapy in locally advanced rectal adenocarcinoma

Michael B. Foote, Jinru Shia, Callahan Wilde, Marinela Capanu, Joanne Chou, Vetri Sudar Jayaprakasam, Marc Gollub, Miteshkumar Patel, Mina Ito, Leonard B. Saltz, Devika Rao, Neil Segal, Maliha Nusrat, Karuna Ganesh, Paul Romesser, Julio Garcia-Aguilar, Martin Weiser, Rona Yaeger, Luis A. Diaz, Andrea Cercek

Read the abstract →
CT012
A phase 2 single-arm open-label trial evaluating zanidatamab in patients with early stage HER2 positive breast cancer: The NeoZanHER Study

Vicente Valero, Paula R. Pohlmann, Jason Mouabbi, Xuelin Huang, Wei Qiao, Heather R. Alonzo, Rashmi Krishna Murthy, Gaiane M. Rauch, Taiwo Adesoye, Cristina M. Checka, William F. Symmans, Dmitri Grachev, Flora Alajajyan, Adaeze Nwosu-Iheme, Amy Hassan, Miral Mahesh Patel, Sharon H. Giordano, Kelly Hunt, Debasish Tripathy, Funda Meric-Bernstam

Read the abstract →
CT045
Initial clinical and translational results and selection of recommended phase 2 dose (RP2D) from START-002: A Phase 1b/2 study of invikafusp alfa, a first-in-class dual T-cell agonist, in combination with sacituzumab govitecan in metastatic triple-negative or HR+/HER2- breast cancer

Steven J Isakoff, Anastasia Martynova, Philippe L Bedard, Margaret E Gatti-Mays, Nathalie LeVasseur, Andreas Varkaris, William Randolph, Karunya Srinivasan, Shannon McCue, Zhenming Shun, Ke Liu, Zhen Su, Kevin Chin, Virginia Kaklamani, Kelly McCann, Erika Hamilton

Read the abstract →
CT262
Elacestrant (Ela) in combination with everolimus (Eve) or abemaciclib (Abema) in patients with ER+/HER2- locally advanced or metastatic breast cancer mBC: phase 2 results from ELEVATE, an open-label, umbrella study

Hope S. Rugo, Sara M. Tolaney, Nancy Chan, Giuliano Borges, Rinat Yerushalmi, Marina N. Sharifi, Wassim McHayleh, Thaddeus Beck, Neelima Vidula, Erika Hamilton, Kristine J. Rinn, Joyce O’Shaughnessy, Giuseppe Curigliano, Javier Cortés, Paula Muñoz Romero, Giulia Tonini, Alessandro Paoli, Monica Binaschi, Li Cheng, Jennifer A. Crozier, Tomer Wasserman, Virginia Kaklamani

Read the abstract →
CT275NCT07151586
ALTER: A randomized Phase II trial evaluating an upfront alternating regimen of sacituzumab-govitecan and trastuzumab-deruxtecan versus sacituzumab-govitecan alone in HER2-low metastatic triple-negative breast cancer (NCT07151586)

Alexandre de Nonneville, Jean-Marie Boher, Jean-Sébastien Frenel, Gerald Bagoe, Olivier Tredan, Marie-Ange Mouret-Reynier, Chayma Bousrih, Vincent Massard, Julien Grenier, Marie Robert, Florence Lerebours, Delphine Loriat, Florence Dalenc, Christelle Jouannaud, Stéphanie Becourt, Philippe Follana, Sylvain Ladoire, William Jacot, Bogdan-Valentin Popescu, Maxime Brunet, George Emile, Jerôme Lemmonier, Sylvie Mijonnet, Anthony Gonçalves, François Bertucci

Read the abstract →
Floor
TodayOct 23Fri
Oct 19Mon
Apr 23Thu
Apr 22Wed
Apr 20Mon
Apr 19Sun
CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org